BRIEF-Amicus Therapeutics presents preclinical data for Pompe program at WORLDSymposium 2017
February 15, 2017 at 08:20 AM EST
* Preclinical studies showed ATB200/AT2221 reversed cellular dysfunction, increased muscle strength over 5 month period in GAA knock-out mice Source text for Eikon: Further company coverage:
